The Data Safety and Monitoring Board has met and evaluated the safety data from the first participant treated with AGT103-T, our HIV-cure drug candidate. The participant experienced no significant adverse events, and the DSMB voted unanimously to "continue the study with no modification".
AGT is now a clinical-stage biotech company with initial safety data on a potential cure for a disease affecting over 1.2 million people in the U.S. and nearly 40 million people globally!